MA27720A1 - Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP - Google Patents

Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP

Info

Publication number
MA27720A1
MA27720A1 MA28498A MA28498A MA27720A1 MA 27720 A1 MA27720 A1 MA 27720A1 MA 28498 A MA28498 A MA 28498A MA 28498 A MA28498 A MA 28498A MA 27720 A1 MA27720 A1 MA 27720A1
Authority
MA
Morocco
Prior art keywords
disorder
sexual
dysfunction
male
female
Prior art date
Application number
MA28498A
Other languages
English (en)
Inventor
David Hepworth
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305916A external-priority patent/GB0305916D0/en
Priority claimed from GB0329143A external-priority patent/GB0329143D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27720A1 publication Critical patent/MA27720A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

l'hypercalciurie, un ictus, le glaucome, l'obésité, des maladies métaboliques, le syndrome métabolique, le diabète, la tolérance entravée au glucose, la rétinopathie diabétique, la neuropathie diabétique, des troubles menstruels, l'accouchement avant terme, la pré-éclampsie, l'endométriose et des troubles de la reproduction, la stérilité masculine et la stérilité féminine, le syndrome d'ovaire polykystique, un défaut d'implantation, l'asthme, l'inflammation, la leucémie, la douleur, la douleur provoquée par un cancer, la dépression, la pharmacodépendance, la cirrhose, l'épilepsie, des troubles affectifs, la démence et la confusion gériatrique, des troubles gastro-intestinaux, la diarrhée, le syndrome du côlon irritable, la cicatrisation de plaies, les ulcères diabétiques et les ulcères veineux et les escarres de décubitus, le choc septique, la sécrétion d'acide gastrique, l'hyperréninémie, la fibrose kystique, une resténose, l'athérosclérose, un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 13. Composé, méthode ou utilisation suivant la revendication 12, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 14. Composé, méthode ou utilisation suivant la revendication 13, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD) et un dysfonctionnement, de l'érection masculine (MED).
MA28498A 2003-03-14 2005-09-14 Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP MA27720A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305916A GB0305916D0 (en) 2003-03-14 2003-03-14 New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en) 2003-12-16 2003-12-16 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
MA27720A1 true MA27720A1 (fr) 2006-01-02

Family

ID=32992599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28498A MA27720A1 (fr) 2003-03-14 2005-09-14 Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP

Country Status (25)

Country Link
US (1) US20040180941A1 (fr)
EP (1) EP1606272A1 (fr)
JP (1) JP3923512B2 (fr)
KR (1) KR20050110003A (fr)
AP (1) AP2005003393A0 (fr)
AR (1) AR043551A1 (fr)
AU (1) AU2004220269A1 (fr)
BR (1) BRPI0408377A (fr)
CA (1) CA2519072A1 (fr)
CL (1) CL2004000512A1 (fr)
EA (1) EA200501204A1 (fr)
EC (1) ECSP056017A (fr)
HR (1) HRP20050797A2 (fr)
IS (1) IS8003A (fr)
MA (1) MA27720A1 (fr)
MX (1) MXPA05009788A (fr)
NL (1) NL1025709C2 (fr)
NO (1) NO20054169L (fr)
OA (1) OA13039A (fr)
PA (1) PA8597401A1 (fr)
PE (1) PE20050310A1 (fr)
TN (1) TNSN05227A1 (fr)
TW (1) TW200504038A (fr)
UY (1) UY28226A1 (fr)
WO (1) WO2004080985A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020291A2 (fr) * 2004-08-02 2006-02-23 Bebaas, Inc. Compositions de vitamine b12
WO2006027680A1 (fr) * 2004-09-10 2006-03-16 Pfizer Limited Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre
CN102861019B (zh) 2004-12-24 2016-05-25 诺华股份有限公司 治疗或预防神经性疼痛的药物
WO2007016361A2 (fr) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Nouveaux composes pharmaceutiques
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
EP2952185A1 (fr) * 2006-03-20 2015-12-09 Spinifex Pharmaceuticals Pty Ltd Méthode de traitement prophylactique ou thérapeutique
EP2051696A2 (fr) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Compositions liquides stables de lévétiracétam et procédés
KR101177866B1 (ko) 2011-03-24 2012-08-28 주식회사 케이엠더블유 케이블 접속 장치
US20190385720A1 (en) * 2018-06-14 2019-12-19 AstraZeneca UK Litimited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
AU2019287546A1 (en) * 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
IL281770B2 (en) 2018-09-25 2025-03-01 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
AU2020377914A1 (en) * 2019-11-08 2022-06-02 Vella Bioscience, Inc. Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
GB202402524D0 (en) * 2024-02-22 2024-04-10 Futura Medical Developments Ltd Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) * 1985-08-05 1987-02-05 Hoechst Ag Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU4844396A (en) * 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
HRP20030751A2 (en) * 2001-03-28 2005-08-31 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Also Published As

Publication number Publication date
US20040180941A1 (en) 2004-09-16
NO20054169L (no) 2005-12-07
OA13039A (en) 2006-11-10
TNSN05227A1 (fr) 2007-06-11
CA2519072A1 (fr) 2004-09-23
WO2004080985A1 (fr) 2004-09-23
NL1025709A1 (nl) 2004-09-16
AR043551A1 (es) 2005-08-03
EA200501204A1 (ru) 2006-06-30
KR20050110003A (ko) 2005-11-22
AP2005003393A0 (en) 2005-09-30
UY28226A1 (es) 2004-11-08
TW200504038A (en) 2005-02-01
PE20050310A1 (es) 2005-05-04
NO20054169D0 (no) 2005-09-07
CL2004000512A1 (es) 2005-01-21
AU2004220269A1 (en) 2004-09-23
BRPI0408377A (pt) 2006-03-21
JP3923512B2 (ja) 2007-06-06
JP2006526572A (ja) 2006-11-24
ECSP056017A (es) 2006-01-27
EP1606272A1 (fr) 2005-12-21
PA8597401A1 (es) 2005-05-24
MXPA05009788A (es) 2005-10-26
HRP20050797A2 (en) 2006-02-28
NL1025709C2 (nl) 2005-03-14
IS8003A (is) 2005-08-29

Similar Documents

Publication Publication Date Title
MA27720A1 (fr) Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP
CN1196483C (zh) 提高生育力的组合物
KR102060379B1 (ko) 6-디플루오로메틸-5,6-디하이드로-2h-[1,4]옥사진-3-아민 유도체
NO168795B (no) Fiberoptisk undervannsledning for telekommunikasjonsformaal
CN1168376A (zh) 制备喜勃酮的方法
NO150839B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 5-(4-pyridyl-6-(4-fluorfenyl)-2,3-dihydroimidazo-(2,1-b)-tiazol
DE1909180A1 (de) Disubstituierte N-Aminoindolinverbindungen und Verfahren zu ihrer Herstellung
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
EP1399151A4 (fr) Procede de traitement de maladies inflammatoires par administration d'un agoniste ppar-delta
NO153001B (no) Drivanordning for skip
RU2447073C2 (ru) Способ получения абакавира
CN100338069C (zh) 制备奥氮平及其中间体的方法
NO155198B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2, 3-difenyl-5-halogenthiofener.
US3853872A (en) 2,3,4,5-substituted thiazoles
EP0644872B1 (fr) Composes aminooxy cycliques inhibiteurs de la decarboxylase d'ornithine
CA2394027A1 (fr) Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US2680767A (en) Pantothenylaminoethyl sulfur compounds and method for obtaining the same
FI81788C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara fenotiazinfoereningar.
DE69814420T2 (de) Stereoselektive verfahren zur herstellung von gabapentinanalogen
JPH0762018B2 (ja) ジヒドロピリジンラクト−ル類
US6369218B1 (en) Isomerisation of 6β-fluorosteroids into the corresponding 6α-fluoro derivatives
US20050267096A1 (en) New indazole and indolone derivatives and their use pharmaceuticals
SU1657062A3 (ru) Способ получени производных 2-тиазолидинона
US3923796A (en) Certain 6,7-dioxo-2H-pyrrolo-{8 2,1-b{9 thiazines
FR2647785A1 (fr) Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant